RTX heads into its July 23 Q2 earnings release with options traders nudging back toward caution — a posture that has proved stubborn across multiple weeks of coverage, even as the stock has stabilised near $193.67.
The options signal is the clearest thing to read in this setup. The put/call ratio has climbed back to 0.91, essentially matching the 52-week high of 0.92 hit in early July, and now running about 1.1 standard deviations above its 20-day average of 0.87. That reverses the brief drift toward neutrality noted earlier in the week and puts protective demand back near its most elevated point of the past year. The price itself has barely moved — flat on the week and up just over 4% on the month — which makes the renewed hedging demand more notable, not less. Investors are not hedging a falling stock; they are hedging into the unknown of the print itself. The borrow market carries no message: with more than 900 million shares available to lend against a short base of just 1.3% of free float and cost to borrow at a negligible 0.44%, the lending side is as frictionless as it comes. Defense peers tell a different story on weekly performance — NOC, LMT, and have all shed 2–5% on the week, while RTX has held flat, suggesting relative resilience rather than sector-wide pressure.
The analyst debate centres on execution and capital allocation rather than growth direction. Bulls argue RTX's dual exposure to commercial aerospace recovery and rising defence budgets creates a durable earnings base, with accelerating free cash flow the key valuation lever. The bear case focuses on the practical constraints: a high-priority debt reduction programme limits buyback flexibility, and any softening in defence appropriations — particularly following recent executive-order uncertainty around defence investment — could dent near-term growth assumptions. The consensus mean target of $215 implies roughly 11% upside from current levels. The most recent directional move worth noting is Jefferies' upgrade to Buy in early June, lifting its target to $220 — the only rating change in the past seven weeks and a modest positive signal heading into the number. Morgan Stanley and UBS both trimmed targets after the April print, a dynamic already absorbed by the market.
The April earnings history adds context. Q1 results in April delivered a sharp one-day drop of 7.6% and a five-day loss of over 10% — a reminder that even a constructively positioned stock can gap hard on guidance disappointment. The most recent print, on April 30, bucked that trend with a modest gain. That inconsistency in reaction patterns is itself informative: RTX has shown it can go either way sharply, which likely explains why hedging demand has not fully unwound despite a quiet few weeks of price action.
The print tomorrow will test whether RTX's free cash flow trajectory and guidance on both the Pratt & Whitney engine overhaul cycle and missile production contracts can justify a valuation running at a trailing P/E of roughly 26.7x — elevated enough that execution precision matters.
See the live data behind this article on ORTEX.
Open RTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
